Aura Biosciences, Inc. AURA
Institutional shares held
39.9 Million
1.9K
calls
31K
puts
Total value of holdings
$304M
$14K
calls
$236K
puts
Market Cap
$220M
29,273,600
Shares Out.
Institutional ownership
136.3%
# of Institutions
95
We take great care to ensure that the data presented and summarized in this overview for Aura Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AURA
View all-
Matrix Capital Management Company, LP Waltham, MA6.92MShares$52 Million2.75% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.88MShares$36.7 Million0.07% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.08MShares$30.6 Million0.64% of portfolio
-
Medicxi Ventures Management (Jersey) LTD3.04MShares$22.8 Million5.49% of portfolio
-
Black Rock Inc. New York, NY3.01MShares$22.6 Million0.0% of portfolio
-
Long Focus Capital Management, LLC San Juan, PR2.54MShares$19.1 Million0.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.92MShares$14.4 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.72MShares$12.9 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.27MShares$9.54 Million0.52% of portfolio
-
Levin Capital Strategies, L.P. New York, NY1.25MShares$9.37 Million1.02% of portfolio
Latest Institutional Activity in AURA
Top Purchases
Top Sells
About AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at AURA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
20,221
-4.02%
|
$141,547
$7.75 P/Share
|
|
Feb 18
2025
|
Janet Jill Hopkins Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,534
-0.93%
|
$17,738
$7.75 P/Share
|
|
Feb 18
2025
|
Amy Elazzouzi Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,404
-1.68%
|
$9,828
$7.75 P/Share
|
|
Feb 18
2025
|
Mark Plavsic Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,151
-1.02%
|
$15,057
$7.75 P/Share
|
|
Feb 03
2025
|
Amy Elazzouzi Senior Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
45,240
+35.09%
|
-
|
|
Feb 03
2025
|
Conor Kilroy |
BUY
Grant, award, or other acquisition
|
Direct |
90,475
+32.67%
|
-
|
|
Feb 03
2025
|
Janet Jill Hopkins Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
120,635
+30.7%
|
-
|
|
Feb 03
2025
|
Mark Plavsic Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,475
+29.95%
|
-
|
|
Feb 03
2025
|
Pinos Elisabet De Los |
BUY
Grant, award, or other acquisition
|
Direct |
194,320
+27.88%
|
-
|
|
Jan 21
2025
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
15,955
-4.98%
|
$111,685
$7.67 P/Share
|
|
Jan 21
2025
|
Amy Elazzouzi Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,001
-2.54%
|
$7,007
$7.67 P/Share
|
|
Nov 18
2024
|
Janet Jill Hopkins Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,822
-7.23%
|
$106,398
$9.36 P/Share
|
|
Oct 29
2024
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
9,200
-2.79%
|
$92,000
$10.74 P/Share
|
|
Oct 29
2024
|
Amy Elazzouzi Senior Vice President, Finance |
SELL
Open market or private sale
|
Direct |
553
-1.38%
|
$5,530
$10.74 P/Share
|
|
Oct 18
2024
|
Julie B Feder Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
25,131
-15.77%
|
$301,572
$12.03 P/Share
|
|
Oct 18
2024
|
Julie B Feder Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,131
+5.02%
|
$100,524
$4.16 P/Share
|
|
Oct 18
2024
|
Pinos Elisabet De Los |
SELL
Open market or private sale
|
Direct |
24,992
-7.04%
|
$299,904
$12.04 P/Share
|
|
Oct 18
2024
|
Pinos Elisabet De Los |
BUY
Exercise of conversion of derivative security
|
Direct |
24,992
+6.58%
|
$49,984
$2.74 P/Share
|
|
Oct 16
2024
|
Mark Plavsic Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
7,383
-5.74%
|
$66,447
$9.85 P/Share
|
|
Sep 27
2024
|
Pinos Elisabet De Los |
BUY
Exercise of conversion of derivative security
|
Direct |
5,474
+1.63%
|
$27,370
$5.76 P/Share
|
Last 12 Months Summary
Buy / Acquisition
724K
Shares
From
10
Insiders
| Grant, award, or other acquisition | 669K shares |
|---|---|
| Exercise of conversion of derivative security | 55.6K shares |
Sell / Disposition
122K
Shares
From
5
Insiders
| Open market or private sale | 122K shares |
|---|